Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

ns for more information on ViroPharma and our business.

Disclosure NoticeCertain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2011, our ability to continue to successfully commercialize Cinryze, our ability to complete manufacturing scale up procedures, and receive regulatory approvals in the time frames anticipated, our ability to manufacture specified quantities of Cinryze utilizing the existing manufacturing process or additional manufacturing procedures; our ability to develop life cycle management plans for Cinryze, including designing and commencing clinical studies for additional indications, and pursuing regulatory approvals in additional territories; and our ability to conduct additional studies in the timeframes we anticipate and generate positive results with a Cinryze subcutaneous formulation, Cinryze for antibody mediated rejection and delayed graft function, as well as VP20621 for recurrence of C. difficile.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to receive regulatory approval for the use of Cinryze for additional indications and formulations and in additional territories including the EU in the timeframes we anticipate or at all;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for each product;
  • our ability to increase manufacturing capacity for Cinryze and the timing and results thereof;
  • our ability to receive necessary regulatory approvals related to manufacturing capacity increases for Cinryze;
  • the
    '/>"/>

  • SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/24/2015)... April 24, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... biosimilar therapeutics including high value and difficult to manufacture ... offering of 6,000,000 shares of its common stock at ... Of the shares being offered, 2,610,000 are being offered ... offered by existing stockholders. Pfenex will not receive any ...
    (Date:4/24/2015)... 24, 2015  Navitas Life Sciences is delighted to announce ... Clinical and Regulatory Services. Shalabh is a proven leader in ... CEO of Kinapse, as well as a Strategy consultant at ... - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... "I am delighted to welcome Shalabh into this critical role ...
    (Date:4/24/2015)... 2015 Seoul Semiconductor announced the ... applications in the lighting market. In recent ... this technology in emerging markets such as Russia, ... range of applications such as streetlight and area ... , First launched in 2005 the Acrich technology ...
    (Date:4/23/2015)... (PRWEB) April 23, 2015 Athena San ... development of executive women in San Diego’s technology and ... 17th Annual Pinnacle Awards at their Gala on April ... Hotel. Register now at http://athenasd.org/events/ , The ... the Athena San Diego vision of fostering networking, risk ...
    Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2
    ... , Abstract ... technologies enable expression array analysis from extremely limited cell mass. ... amplification protocols, and novel quality assurance checks is used in ... with confidence. This application note provides a workflow for laser-cut ...
    ... Key words: LEADseeker • ... , The ... detects and quantitates light from a range of radiometric, luminescence, and fluorescence ... the combination of format-free imaging (fluorescence assays can be read in as ...
    ... , ... receptor binding assay • LEADseeker • SPA Imaging ... In mammals, serotonin (5-hydroxytryptamine, 5-HT) is a regulator of ... <P ,>The serotonin 5-HT 2C receptor is a subtype of ...
    Cached Biology Technology:Microgenomic Expression Profiling 2Microgenomic Expression Profiling 3Microgenomic Expression Profiling 4Microgenomic Expression Profiling 5Microgenomic Expression Profiling 6Microgenomic Expression Profiling 7Integration of the LEADseeker Multimodality Imaging System with automated plate loading and incubation using Overlord Instrument software 2Integration of the LEADseeker Multimodality Imaging System with automated plate loading and incubation using Overlord Instrument software 3Integration of the LEADseeker Multimodality Imaging System with automated plate loading and incubation using Overlord Instrument software 4The development of a serotonin 5-HT2C receptor-binding assay using the LEADseeker Multimodality Imaging System 2The development of a serotonin 5-HT2C receptor-binding assay using the LEADseeker Multimodality Imaging System 3The development of a serotonin 5-HT2C receptor-binding assay using the LEADseeker Multimodality Imaging System 4
    (Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
    (Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
    (Date:3/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces its biometric payment technology, ... featured in 2015 "I Want That" International CES Special, ... the DIY Network.   DIY,s "I Want ... site of the 2015 International CES for a firsthand ...
    Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
    ... contribute to the greenhouse gas emissions that are causing climate change. ... How we travel, what we eat, what we consume and what ... our carbon footprint . How, though, do we measure ... to find out on April 26, when Louis S. Santiago ...
    ... children in the United States are obese, and in inner-city ... diets and physical inactivity are the main culprits, there is ... A study by Columbia University,s Mailman School of Public ... to higher concentrations of chemicals called polycyclic aromatic hydrocarbons, or ...
    ... of the most common types of human leukemia may ... to new research led by physician-scientists at the University ... Cancer Center. Published this week in the journal ... in the FLT3 gene as targets for acute myeloid ...
    Cached Biology News:Measuring our carbon footprint 2Prenatal exposure to air pollution linked to childhood obesity 2Prenatal exposure to air pollution linked to childhood obesity 3An Achilles heel of AML 2An Achilles heel of AML 3
    Phospho-MEF2A(Thr312)...
    IHC Select Anti-p53, prediluted,wild & mutant, a.a. 19-26, clone DO-7 Immunogen: Human p53 Available Date: 37775...
    Anti-human Carcinoma Associated Antigen, Clone 115D8, Monoclonal Antibody Innate Immunity - Tumor Markers...
    Ezrin/Radixin/Moesin Antibody...
    Biology Products: